Folixate (Folate, Vitamin D3)
Brand Names: Folixate
Methodology & AI Transparency ⓘ
Folixate (Folate, Vitamin D3) Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Folixate (Folate, Vitamin D3) represents a prescription brand-name folate analog entry registered by PureTek Corporation with package codes 59088-301.
- 2 Real-world patient consensus: Branded folate analog presentation of Folate, Vitamin D3 (PureTek Corporation); generic reference RxCUI 2671090.
- 3 Typical cash cost range: 30-day cash pricing ranges from $62.50 discount cash to $165.63 walk-in retail (NADAC $0.7500/unit).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Folixate (Folate, Vitamin D3)): nausea (9.1%), headache (7.4%), dizziness (5.2%).
Ask our AI Specialists anything about Folixate (Folate, Vitamin D3)
Folixate (Folate, Vitamin D3) Mechanism, CYP450 Pathways & DailyMed Monograph
Folixate (Folate, Vitamin D3) represents a prescription brand-name folate analog entry registered by PureTek Corporation with package codes 59088-301. Reviewed against 2023-12-05 FDA SPL standards (1000 ug/1 / 125 ug/1 Tablet; Prescriber-supervised Folate, Vitamin D3 escalation or taper window), clinical deployment addresses Folixate ™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate level.
Folixate achieves therapeutic action via Folate, Vitamin D3, engaging folate analog physiological pathways with class-characteristic hepatorenal disposition. Manufactured in 1000 ug/1 / 125 ug/1 Tablet; Prescriber-supervised Folate, Vitamin D3 escalation or taper window (registered by PureTek Corporation, NDC 59088-301), pharmacists evaluate FDA Orange Book therapeutic equivalence when comparing branded Folixate ($165.63 retail) with generic Folate, Vitamin D3 ($62.50 low cash).
Following administration (1000 ug/1 / 125 ug/1 Tablet), Folixate (Folate, Vitamin D3) achieves Oral fraction absorbed ranges from 57% to 69% (Folixate (Folate, Vitamin D3) 1000) bioavailability and oral tmax achieved within 2 to 4 hours following folixate (folate, vitamin d3) ingestion onset, governed by a Mean elimination half-life of 4 to 10 hours across adult Folixate (Folate, Vitamin D3) dosing terminal half-life through dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of folixate (folate, vitamin d3).
Before initiating Folixate (Folate, Vitamin D3) at 1000 ug/1 / 125 ug/1 Tablet, clinical safety checklists rule out contraindicated in patients with prior serious allergic response to folixate (folate, vitamin d3) (ndc 59088-301); severe baseline organ impairment where folate, vitamin d3 accumulation exceeds safe therapeutic margins. Logged tolerability patterns center on nausea (9.1% of reports), headache (7.4% of reports), dizziness (5.2% of reports).
Separate Folixate (Folate, Vitamin D3) ingestion from mineral supplements or antacids to preserve gastrointestinal bioavailability.
Reconcile eGFR-adjusted medications before escalating Folixate (Folate, Vitamin D3) in polypharmacy regimens.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Contraindicated in patients with prior serious allergic response to Folixate (Folate, Vitamin D3) (NDC 59088-301)
- Severe baseline organ impairment where Folate, Vitamin D3 accumulation exceeds safe therapeutic margins
Logged Side-Effect Incidence (17 Reports)
Folixate (Folate, Vitamin D3) Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Folixate (Folate, Vitamin D3))
Human clinical trial evidence for Folixate (Folate, Vitamin D3) is indexed directly from the U.S. National Library of Medicine NCBI PubMed database. Explore recent randomized trials in the PubMed Research Pulse .
Folixate (Folate, Vitamin D3) Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.7500/unit (~$22.50/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $165.63 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 17 Anonymous DotMD Community Micro-Logs | $62.50 / mo | View logs ↓ |
Folixate (Folate, Vitamin D3) Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Folixate (Folate, Vitamin D3) RxNorm Concept ID | 2671090 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.7500 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $165.63 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $62.50 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 93.00% Worth It (17 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Folixate (Folate, Vitamin D3) Patient Community, Cohort Filters & Dosage Logs
Evidence synthesis for Folixate (Folate, Vitamin D3): FDA labeling (2023-12-05, NDC 59088-301), CYP/interaction screening, and public pharmacy acquisition costs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Folixate (Folate, Vitamin D3) community threads and patient logs by age, biological sex, dosage, and treatment duration.